文献速递泌尿男性生殖肿瘤

醋酸阿比特龙用于激素诱导后生化反应欠佳的转移性前列腺癌患者

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
PubMed 文献 · JAMA Oncol · 2017-11-09

这项2期单臂研究纳入41例转移性前列腺癌患者,这些患者在ADT开始后6至12个月PSA仍高于4.0 ng/mL。所有患者接受醋酸阿比特龙1000 mg每日一次联合泼尼松5 mg每日两次治疗。主要终点为12个月内PSA≤0.2 ng/mL,5例(13%)达到,未达到预设的6例应答水平;中位无进展生存期17.5个月,中位总生存期25.8个月。

要点

  • 41例患者入组,40例可分析,5例(13%)达到PSA≤0.2 ng/mL的主要终点。
  • 另有13例(33%)达到部分缓解(PSA<4.0但>0.2 ng/mL)。
  • 中位无进展生存期17.5个月,中位总生存期25.8个月。

核心结论

  • 本研究未达到预设的6例PSA≤0.2 ng/mL应答水平,但观察到5例应答。
  • 与历史对照相比,本试验观察到的总生存期和无进展生存期令人鼓舞。
  • 该疗法总体耐受良好,未发现任何明确的其他意外不良反应信号。

研究设计与样本

  • 2期单臂研究,通过国家临床试验网络-西南肿瘤学组开展。
  • 纳入标准:转移性前列腺癌,ADT开始后6至12个月PSA高于4.0 ng/mL;入组时PSA可升可降但须高于4.0 ng/mL;不允许既往化疗或二线激素治疗,但入组时正在接受标准第一代抗雄激素且PSA下降者可继续该治疗。
  • 2011年8月9日试验启动至2013年8月1日关闭期间共入组41例男性患者。
  • 所有参与者接受醋酸阿比特龙1000 mg每日一次口服联合泼尼松5 mg每日两次口服。
  • 数据分析于2016年3月21日至11月29日进行。

主要发现

  • 41例入组患者中1例未接受任何方案治疗并被排除分析。
  • 40例可分析患者的中位(范围)年龄为66(39-85)岁。
  • 5例(13%)患者达到PSA≤0.2 ng/mL(95% CI,4%-27%)。
  • 另有13例(33%)患者达到部分缓解,即PSA降至低于4.0 ng/mL但高于0.2 ng/mL。
  • 16例(40%)患者无PSA应答,6例(15%)不可评估并假定为无应答者。

关键数值与推荐

  • 主要终点:开始醋酸阿比特龙联合泼尼松治疗后12个月内PSA≤0.2 ng/mL。
  • 部分缓解(次要终点)定义:PSA降至低于4.0 ng/mL但高于0.2 ng/mL。
  • 中位无进展生存期17.5个月(95% CI,8.6-25.0个月)。
  • 中位总生存期25.8个月(95% CI,15.7-25.8个月)。
  • 不良事件:丙氨酸氨基转移酶升高和直肠出血各发生1例4级不良事件;11例患者报告3级不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Men with metastatic prostate cancer who have a poor response to initial androgen-deprivation therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4.0 ng/mL after 7 months of ADT, have a poor prognosis, based on historical controls. OBJECTIVE: To determine the efficacy of abiraterone acetate with prednisone in these high-risk patients with a suboptimal response to hormonal induction. DESIGN, SETTING, AND PARTICIPANTS: A phase 2 single-arm study was conducted through the National Clinical Trials Network-Southwest Oncology Group. Eligible patients had metastatic prostate cancer and a PSA level higher than 4.0 ng/mL between 6 and 12 months after starting ADT. The PSA level could be rising or falling at the time of enrollment, but had to be higher than 4.0 ng/mL. No previous chemotherapy or secondary hormonal therapies were allowed, except in patients receiving a standard, first-generation antiandrogen agent with a falling PSA level at the time of enrollment; this therapy was continued in this cohort. Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily was administered to all participants. A total of 41 men were enrolled between the trial's activation on August 9, 2011, and closure on August 1, 2013. Data analysis was conducted from March 21 to November 29, 2016. INTERVENTIONS: Abiraterone acetate, 1000 mg, once daily by mouth with prednisone, 5 mg, by mouth twice daily. MAIN OUTCOMES AND MEASURES: The primary end point was a PSA level of 0.2 ng/mL or lower within 12 months of starting abiraterone acetate plus prednisone. A partial response (PR) was a secondary end point, defined as a PSA level reduction to lower than 4.0 ng/mL but higher than 0.2 ng/mL. RESULTS: Of the 41 men enrolled, 1 did not receive any protocol treatment and was excluded from analysis. The median (range) age of the 40 participants was 66 (39-85) years. Five (13%) patients achieved a PSA level of 0.2 ng/mL or lower (95% CI, 4%-27%). Thirteen (33%) additional patients achieved a partial response, with a reduction in the PSA level to lower than 4.0 ng/mL but higher than 0.2 ng/mL. Sixteen (40%) patients had no PSA response and 6 (15%) were not assessable and assumed to be nonresponders. The median progression-free survival was 17.5 months (95% CI, 8.6-25.0 months) and the median overall survival was 25.8 months (95% CI, 15.7-25.8 months). There was 1 incident each of grade 4 adverse events of alanine aminotransferase level elevation and rectal hemorrhage. Eleven patients reported grade 3 adverse events. CONCLUSIONS AND RELEVANCE: This study did not reach its prescribed level of 6 PSA responses of 0.2 ng/mL or lower, although 5 responses were observed. The overall survival and progression-free survival rates observed in this trial are encouraging compared with historical controls. The therapy was generally well tolerated, without any clear signal of any unexpected adverse effects.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Flaig TW, Plets M, Hussain MHA, et al. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017. PMID: 28358937. doi:10.1001/jamaoncol.2017.0231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。